Hydracort (Hydrocortisone)

Hydracort (hydrocortisone) is indicated for several medical conditions that require glucocorticoid therapy.

• Replacement therapy for primary or secondary adrenal insufficiency (e.g., Addison’s disease).
• Management of acute inflammatory episodes in autoimmune disorders such as rheumatoid arthritis or systemic lupus erythematosus.
• Treatment of severe allergic reactions, including anaphylaxis, when oral therapy is appropriate.
• Adjunctive therapy for certain endocrine disorders requiring cortisol supplementation.
• Short‑term control of inflammation in dermatologic or gastrointestinal conditions when oral administration is preferred.

• Hydrocortisone penetrates cell membranes and binds to intracellular glucocorticoid receptors. The hormone‑receptor complex translocates to the nucleus, where it interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokines. This genomic effect reduces leukocyte migration, stabilizes lysosomal membranes, and decreases capillary permeability, collectively producing anti‑inflammatory and immunosuppressive actions. Additionally, non‑genomic pathways may contribute to rapid membrane‑stabilizing effects.

Oral hydrocortisone can cause a range of adverse reactions, which vary in frequency and severity.

Common

• Mild gastrointestinal discomfort, such as nausea or dyspepsia.
• Transient increase in blood glucose levels, especially in patients with diabetes.
• Fluid retention leading to mild peripheral edema.
• Mood changes including irritability or mild insomnia.
• Skin thinning or easy bruising.

Serious

• Significant hyperglycemia or new‑onset diabetes mellitus.
• Severe electrolyte disturbances, such as hypokalemia or hypertension.
• Opportunistic infections due to immunosuppression.
• Adrenal crisis on abrupt discontinuation after prolonged therapy.
• Severe psychiatric effects such as psychosis or depression.

Before initiating Hydracort, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases.
• Screen for uncontrolled diabetes or hypertension, which may be exacerbated by therapy.
• Evaluate for a history of peptic ulcer disease or gastrointestinal bleeding.
• Use the lowest effective dose for the shortest duration necessary to reduce adverse effects.
• Monitor electrolyte balance, especially potassium and sodium levels, during prolonged treatment.
• Counsel patients on the need for gradual tapering to avoid adrenal insufficiency after long‑term use.

Hydrocortisone may interact with other medicines, altering its effectiveness or increasing toxicity.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that can reduce hydrocortisone levels.
• Combining with other systemic corticosteroids, which may amplify immunosuppressive and metabolic effects.

Use with caution

• Anticoagulants such as warfarin, where glucocorticoids can affect INR.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), increasing the risk of gastrointestinal ulceration.
• Vaccines, particularly live attenuated vaccines, due to possible reduced immune response.
• Diabetic agents, as hydrocortisone may raise blood glucose and require dose adjustment.
• Antihypertensive medications, especially ACE inhibitors, may have altered efficacy.